ArticleActa neuropathologica2017
Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy.
Abstract readEditorial
In one paragraph
Article in Acta neuropathologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.Journal of neuro-oncology · 2020Pooled it
- cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.Brain pathology (Zurich, Switzerland) · 2020Guideline
- Understanding the difference in symptoms and outcomes between glioblastoma patients diagnosed based on histological or molecular criteria: a retrospective cohort analysis from the Histo-Mol GBM collaborative.Journal of neuro-oncology · 2026Article
- Treatment differences in IDH-wildtype glioma - the impact of surgery and adjuvant therapy.Journal of neuro-oncology · 2025Article
- Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a "molecular" glioblastoma.The oncologist · 2025Article
- The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma.International journal of molecular sciences · 2025Review
- Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.Molecular cancer · 2025Review
- Clinical and Imaging Features of Head and Neck Metastasis of High-Grade Glioma: A Single-Center Case Series.AJNR. American journal of neuroradiology · 2025Article
- Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP.Journal of pathology and translational medicine · 2024Review
- Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP.Cancer research and treatment · 2024Review
- Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.Journal of neuropathology and experimental neurology · 2024Article
- Imaging Features of Primary Intracranial Sarcoma withAJNR. American journal of neuroradiology · 2024Article
- D-Loop Mutations as Prognostic Markers in Glioblastoma-A Pilot Study.International journal of molecular sciences · 2024Article
- Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.Journal of neuro-oncology · 2024Article
- Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.Journal of neuro-oncology · 2024Article
- Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy.International journal of molecular sciences · 2024Review
- Daily management of gliomas, glioneuronal, and neuronal tumors in the era of the 2021 WHO classification of nervous tumors.Frontiers in neurology · 2024Article
- Molecular Profiling and Targeted Therapies in Gliomas.Current neurology and neuroscience reports · 2023Review
- Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.Cancer medicine · 2023Article
- HN-CLEAR: Head and Neck Consensus Language for Ease and Reproducibility, a Multidisciplinary Consensus Mechanism for Head and Neck Pathology.Head and neck pathology · 2023Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors.
David N LouisPathology Service, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, WRN225, 55 Fruit Street, Boston, MA, 02114, USA. dlouis@mgh.harvard.edu.
Ken AldapeDepartment of Pathology, Princess Margaret Hospital, Toronto, Canada.
Daniel J BratDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
David CapperDepartment of Neuropathology, Institute of Pathology, Ruprecht-Karls-University, Heidelberg, Germany.
David W EllisonDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Cynthia HawkinsDepartment of Paediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Werner PaulusInstitute of Neuropathology, University Hospital Munster, Münster, Germany.
Arie PerryDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Guido ReifenbergerDepartment of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
Dominique Figarella-BrangerDepartment of Pathology and Neuropathology, La Timone Hospital, Aix Marseille University, Marseille, France.
Pieter WesselingDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
Tracy T BatchelorDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
J Gregory CairncrossDepartment of Clinical Neurosciences, University of Calgary, Calgary, Canada.
Stefan M PfisterDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
Stefan RutkowskiDepartment of Pediatric Haematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Michael WellerDepartment of Neurology, University Hospital Zürich, Zurich, Switzerland.
Wolfgang WickGerman Cancer Consortium (DKTK) Core Center Heidelberg, Heidelberg, Germany.
Andreas von DeimlingDepartment of Neuropathology, Institute of Pathology, Ruprecht-Karls-University, Heidelberg, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Consensus Statements as TopicCentral Nervous System NeoplasmsHumans
Identifiers
PMID
27909809What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.